April 3, 2017, San Diego and Beijing -- Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced the order of 25 Illumina NovaSeq 6000 sequencers. Five of the sequencers will be located in the U.S. In addition, Novogene will operate the 20 units purchased by Nanjing Yangzi State Owned Investment Group in China. With the addition of these new NovaSeq sequencers to its existing array of 30 Illumina HiSeq X and 10 PacBio Sequel systems, Novogene now offers the largest and most advanced sequencing capacity in the world with annual throughput of 280,000 human whole genomes.
The addition of the NovaSeq sequencers not only expands Novogene’s sequencing capacity, but also greatly reduces its sequencing cycle times. With NovaSeq, Novogene will be able to sequence up to 48 human whole genomes, producing 6Tb of data, per single run as short as 40 hours. To match NovaSeq’s high capacity and efficiency, Novogene also upgraded its data storage and computing power to 878T flops, total memory of 368TB, and total storage of 29PB.
Introduced by Illumina in January 2017, NovaSeq is a highly powerful sequencer designed to be scalable and flexible for virtually any genome, method, and scale of project. In human disease research, Novogene’s addition of the NovaSeq sequencing platform will enable the study of rare genetic variations with larger sample size, greater depth and faster speed, and accelerate the progress of global precision medical research.
“We were among the first to receive Illumina’s HiSeq X sequencers when
they were first introduced, so we are pleased to now be among the first to
adopt the new NovaSeq sequencing system,” stated Ruiqiang Li, Ph.D.,
Founder and CEO of Novogene. “We look forward to bringing the benefits
of this powerful new sequencing system to our customers through
affordable, flexible and scalable solutions for their diverse research needs.”
About Novogene Corporation
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with
cutting edge NGS and bioinformatics expertise and one of the largest
sequencing capacities in the world. Novogene utilizes scientific excellence, a
commitment to customer service and unsurpassed data quality to help our
clients realize their research goals in the rapidly evolving world of
genomics. With 1,300 employees, multiple locations around the world, 49
NGS related patents, and over 250 publications in top tier journal such as
Nature and Science, the company has rapidly become a world-leader in NGS
services. For more information, visit http://en.novogene.com/.
Joyce Peng, Ph.D.
Global Marketing Director